1951 NW 7TH AVENUE, MIAMI, FL
Changes in Board, Management or Compensation
Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Other Events
Announces 1-for-10 Reverse Stock Split
Appoints Nirav Jhaveri as Chief Financial Officer
Announces 2026 Second Quarter Financial Results and Provides Business Update
Revised Agreement for CEO Stephen Willard - Salary Adjustment and Bonus Eligi...
Q2
Q1
FY 2025
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
S-1
Notice of Exempt Offering of Securities
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(4)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload